New SEC Form D filing

GT Biopharma, Inc., 2026-09-29

A new SEC Form D private-offering notice from San Francisco, CA, a $38,958,054 filer-stated offering target in Biotech. The source filing is one click away.

What this filing says

GT Biopharma, Inc. site↗ Verified via SEC Form D

Clinical stage immuno-oncology company developing NK cell engager (TriKE) therapeutics for cancers including leukemia, lymphoma and solid tumors

Filed 3 days agoFiled to raise $38,958,054First money in 2026-09-14Raised so far $7,750,000HQ (as filed) San Francisco, CASector Biotech web-verified against the company’s own siteStage (inferred) GrowthCall status Call-ready
Source linked the Form D on EDGAR↗Website verified gtbiopharma.com↗Named in the filing 5 executives & directors
Open this row on the live feed →More new filings in California →More Biotech filings →

This is a public SEC Form D private-offering notice, the filer's own statement to the SEC. Amounts are offering targets, not confirmed closes. Takeoff Radar pulls Form D nightly from EDGAR and links every filing to its source.

Other Form D filings from the same week

each with its own page and its own EDGAR source